Accendra Health (ACH) Competitors

$0.09 0.00 (0.00%)
As of 11/20/2026

ACH vs. PRPO, BTMD, RYOJ, DCGO, and PIII

Should you buy Accendra Health stock or one of its competitors? Accendra Health's main competitors and comparable companies include Precipio (PRPO), biote (BTMD), RYOJ (RYOJ), DocGo (DCGO), and P3 Health Partners (PIII). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Accendra Health compare to Precipio?

Accendra Health (NYSE:ACH) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Precipio has a net margin of -4.12% compared to Accendra Health's net margin of -6.72%. Accendra Health's return on equity of -4.02% beat Precipio's return on equity.

Company Net Margins Return on Equity Return on Assets
Accendra Health-6.72% -4.02% -0.83%
Precipio -4.12%-7.84%-5.37%

Accendra Health has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Precipio has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

In the previous week, Accendra Health had 6 more articles in the media than Precipio. MarketBeat recorded 6 mentions for Accendra Health and 0 mentions for Precipio. Precipio's average media sentiment score of 0.05 beat Accendra Health's score of -0.06 indicating that Precipio is being referred to more favorably in the news media.

Company Overall Sentiment
Accendra Health Neutral
Precipio Neutral

Accendra Health presently has a consensus target price of $1.50, suggesting a potential upside of 1,650.29%. Given Accendra Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Accendra Health is more favorable than Precipio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accendra Health
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Precipio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Precipio has lower revenue, but higher earnings than Accendra Health. Precipio is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accendra Health$2.55B0.00-$1.10B-$2.22N/A
Precipio$24.05M1.29-$360K-$0.59N/A

10.5% of Precipio shares are owned by institutional investors. 0.6% of Accendra Health shares are owned by insiders. Comparatively, 16.6% of Precipio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Accendra Health beats Precipio on 8 of the 15 factors compared between the two stocks.

How does Accendra Health compare to biote?

Accendra Health (NYSE:ACH) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

biote has a net margin of -1.08% compared to Accendra Health's net margin of -6.72%. Accendra Health's return on equity of -4.02% beat biote's return on equity.

Company Net Margins Return on Equity Return on Assets
Accendra Health-6.72% -4.02% -0.83%
biote -1.08%-8.61%4.61%

21.7% of biote shares are owned by institutional investors. 0.6% of Accendra Health shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Accendra Health has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, biote has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

biote has lower revenue, but higher earnings than Accendra Health. biote is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accendra Health$2.55B0.00-$1.10B-$2.22N/A
biote$192.22M0.15$27.05M-$0.10N/A

In the previous week, Accendra Health had 4 more articles in the media than biote. MarketBeat recorded 6 mentions for Accendra Health and 2 mentions for biote. biote's average media sentiment score of 0.00 beat Accendra Health's score of -0.06 indicating that biote is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Accendra Health
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
biote
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Accendra Health currently has a consensus price target of $1.50, suggesting a potential upside of 1,650.29%. biote has a consensus price target of $2.50, suggesting a potential upside of 205.25%. Given Accendra Health's higher probable upside, equities research analysts clearly believe Accendra Health is more favorable than biote.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accendra Health
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
biote
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Summary

biote beats Accendra Health on 12 of the 17 factors compared between the two stocks.

How does Accendra Health compare to RYOJ?

Accendra Health (NYSE:ACH) and RYOJ (NASDAQ:RYOJ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

In the previous week, Accendra Health had 4 more articles in the media than RYOJ. MarketBeat recorded 6 mentions for Accendra Health and 2 mentions for RYOJ. RYOJ's average media sentiment score of 1.00 beat Accendra Health's score of -0.06 indicating that RYOJ is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Accendra Health
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
RYOJ
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

RYOJ has lower revenue, but higher earnings than Accendra Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accendra Health$2.55B0.00-$1.10B-$2.22N/A
RYOJ$9.34M2.70$120KN/AN/A

Accendra Health currently has a consensus target price of $1.50, suggesting a potential upside of 1,650.29%. Given Accendra Health's stronger consensus rating and higher probable upside, research analysts plainly believe Accendra Health is more favorable than RYOJ.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accendra Health
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
RYOJ
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Accendra Health has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, RYOJ has a beta of 4.77, meaning that its share price is 377% more volatile than the broader market.

RYOJ has a net margin of 0.00% compared to Accendra Health's net margin of -6.72%. RYOJ's return on equity of 0.00% beat Accendra Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Accendra Health-6.72% -4.02% -0.83%
RYOJ N/A N/A N/A

Summary

RYOJ beats Accendra Health on 7 of the 11 factors compared between the two stocks.

How does Accendra Health compare to DocGo?

DocGo (NASDAQ:DCGO) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

56.4% of DocGo shares are owned by institutional investors. 5.1% of DocGo shares are owned by company insiders. Comparatively, 0.6% of Accendra Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

DocGo currently has a consensus price target of $1.50, suggesting a potential upside of 757.14%. Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 1,650.29%. Given Accendra Health's higher probable upside, analysts clearly believe Accendra Health is more favorable than DocGo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DocGo
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Accendra Health
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Accendra Health has a net margin of -6.72% compared to DocGo's net margin of -60.96%. Accendra Health's return on equity of -4.02% beat DocGo's return on equity.

Company Net Margins Return on Equity Return on Assets
DocGo-60.96% -63.66% -33.31%
Accendra Health -6.72%-4.02%-0.83%

In the previous week, Accendra Health had 5 more articles in the media than DocGo. MarketBeat recorded 6 mentions for Accendra Health and 1 mentions for DocGo. DocGo's average media sentiment score of 0.00 beat Accendra Health's score of -0.06 indicating that DocGo is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DocGo
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Accendra Health
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

DocGo has higher earnings, but lower revenue than Accendra Health. DocGo is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DocGo$322.20M0.05-$182.40M-$1.85N/A
Accendra Health$2.55B0.00-$1.10B-$2.22N/A

DocGo has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Summary

DocGo and Accendra Health tied by winning 8 of the 16 factors compared between the two stocks.

How does Accendra Health compare to P3 Health Partners?

Accendra Health (NYSE:ACH) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Accendra Health had 6 more articles in the media than P3 Health Partners. MarketBeat recorded 6 mentions for Accendra Health and 0 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.00 beat Accendra Health's score of -0.06 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company Overall Sentiment
Accendra Health Neutral
P3 Health Partners Neutral

7.8% of P3 Health Partners shares are owned by institutional investors. 0.6% of Accendra Health shares are owned by company insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

P3 Health Partners has a net margin of -3.30% compared to Accendra Health's net margin of -6.72%. P3 Health Partners' return on equity of 0.00% beat Accendra Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Accendra Health-6.72% -4.02% -0.83%
P3 Health Partners -3.30%N/A -9.38%

Accendra Health currently has a consensus price target of $1.50, indicating a potential upside of 1,650.29%. P3 Health Partners has a consensus price target of $13.67, indicating a potential upside of 708.68%. Given Accendra Health's higher probable upside, research analysts clearly believe Accendra Health is more favorable than P3 Health Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accendra Health
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Accendra Health has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

P3 Health Partners has lower revenue, but higher earnings than Accendra Health. P3 Health Partners is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accendra Health$2.55B0.00-$1.10B-$2.22N/A
P3 Health Partners$1.46B0.01-$147.95M-$23.26N/A

Summary

P3 Health Partners beats Accendra Health on 10 of the 16 factors compared between the two stocks.

Get Accendra Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACH vs. The Competition

MetricAccendra HealthHealthcare Providers & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$6.60M$9.75B$7.44B$20.37B
Dividend YieldN/A2.58%2.51%3.97%
P/E Ratio-0.0432.3132.5627.91
Price / Sales0.001.877.713.41
Price / Cash0.0221.6320.2514.62
Price / Book-0.013.574.343.40
Net Income-$1.10B$329.93M$3.51B$1.07B
7 Day PerformanceN/A-7.06%-8.07%-7.13%
1 Month PerformanceN/A-7.73%-10.29%-7.56%
1 Year PerformanceN/A10.82%-4.70%0.53%

Accendra Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACH
Accendra Health
1.4694 of 5 stars
$0.09
flat
$1.50
+1,650.3%
N/A$6.60M$2.55BN/A6,500
PRPO
Precipio
0.5878 of 5 stars
$23.25
-6.3%
N/A-29.2%$41.62M$27.76MN/A71
BTMD
biote
1.528 of 5 stars
$1.03
-5.5%
$2.50
+142.7%
-68.7%$37.01M$183.53MN/A223
RYOJ
RYOJ
1.0291 of 5 stars
$2.58
+0.4%
N/AN/A$29.80M$9.34MN/A313
DCGO
DocGo
2.1143 of 5 stars
$0.23
-3.0%
$1.50
+566.7%
-81.9%$22.26M$297.34MN/A3,568

Related Companies and Tools


This page (NYSE:ACH) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners